|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500106082 |
|
最近更新日期: Date of Last Refreshed on: |
2025-07-17 09:26:21 |
|
注册时间: Date of Registration: |
2025-07-17 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
吲哚菁绿荧光示踪引导达芬奇机器人手术系统辅助胃癌根治术 |
|
Public title: |
Indocyanine Green Fluorescence-Guided Da Vinci Robotic Surgical System Assisted Radical Gastrectomy for Gastric Cancer |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
吲哚菁绿荧光示踪引导达芬奇机器人手术系统辅助胃癌根治术 |
|
Scientific title: |
Indocyanine Green Fluorescence-Guided Da Vinci Robotic Surgical System Assisted Radical Gastrectomy for Gastric Cancer |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
范义川 |
研究负责人: |
范义川 |
|
Applicant: |
Yichuan Fan |
Study leader: |
Yichuan Fan |
|
申请注册联系人电话: Applicant telephone: |
+86 188 4260 2583 |
研究负责人电话: Study leader's telephone: |
+86 188 4260 2583 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
yichuanfan@126.com |
研究负责人电子邮件: Study leader's E-mail: |
yichuanfan@126.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
辽宁省大连市西岗区中山路222号 |
研究负责人通讯地址: |
辽宁省大连市西岗区中山路222号 |
|
Applicant address: |
No. 222, Zhongshan Road, Xigang District, Dalian City, Liaoning Province, China |
Study leader's address: |
No. 222, Zhongshan Road, Xigang District, Dalian City, Liaoning Province, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
大连医科大学附属第一医院 |
||
|
Applicant's institution: |
The First Affiliated Hospital of Dalian Medical University |
||
|
研究负责人所在单位: |
大连医科大学附属第一医院 |
||
|
Affiliation of the Leader: |
The First Affiliated Hospital of Dalian Medical University |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
PJ-KS-KY-2024-202(X) |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
大连医科大学附属第一医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of the First Affiliated Hospital of Dalian Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-05-28 00:00:00 |
||
|
伦理委员会联系人: |
徐蕾 |
||
|
Contact Name of the ethic committee: |
Lei Xu |
||
|
伦理委员会联系地址: |
辽宁省大连市西岗区中山路222号 |
||
|
Contact Address of the ethic committee: |
No. 222, Zhongshan Road, Xigang District, Dalian City, Liaoning Province, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 411 8363 5963 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
大连医科大学附属第一医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The First Affiliated Hospital of Dalian Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
辽宁省大连市西岗区中山路222号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 222, Zhongshan Road, Xigang District, Dalian City, Liaoning Province, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
国家自然科学基金 |
||||||||||||||||||||||
|
Source(s) of funding: |
National Natural Science Foundation of China (NSFC) |
||||||||||||||||||||||
|
Target disease: |
Gastric cancer |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
探讨ICG示踪引导下达芬奇机器人手术系统胃癌根治术的疗效及安全性分析,并研究该技术是否可以改善机器人胃癌根治术中淋巴结的可视化水平。 |
||||||||||||||||||||||
|
Objectives of Study: |
Study on the Efficacy and Safety of ICG -Guided Da Vinci Robotic Radical Gastrectomy for Gastric Cancer: With Focus on Its Potential to Improve Lymph Node Visualization. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1: 18岁≤年龄≤85岁,男女不限 2: 活组织病理学检查证实为胃癌(cT1~4aN0~3M0 期) 3: ECOG 体力状况评分为 0 分或 1 分 4: ASA 分级≤Ⅲ级 |
||||||||||||||||||||||
|
Inclusion criteria |
1.Age: 18 to 85 years (inclusive), regardless of gender. 2.Pathologically confirmed gastric adenocarcinoma (clinical stage: cT1–4a, N0–3, M0) via biopsy. 3.ECOG Performance Status: 0 or 1. 4.ASA Physical Status Classification: ≤ Class III. |
||||||||||||||||||||||
|
排除标准: |
1: 残胃癌 2: 因胃肿瘤出血、穿孔或梗阻行急诊手术 3: 有上腹部手术史(LC除外) 4: 已行内镜黏膜下剥离术后行补救手术 5: 有其他恶性肿瘤病史,或检查发现合并其他恶性肿瘤 |
||||||||||||||||||||||
|
Exclusion criteria: |
1.Gastric stump cancer (cancer occurring in the residual stomach after prior gastrectomy). 2.Emergency surgery due to tumor-related complications (bleeding, perforation, or obstruction). 3.History of upper abdominal surgery (excluding laparoscopic cholecystectomy). 4.Salvage surgery following endoscopic submucosal dissection (ESD). 5.History of other malignancies, or concurrent diagnosis of other malignant tumors. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-04-18 00:00:00至 To 2025-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2024-04-21 00:00:00 至 To 2025-12-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
给定种子数和区段长度,应用 SAS9.2 编程产生流水号为 01~60 所对应的治疗分配,在数据中心存留。按照 1:1 比例随机分配病例至ICG 组和非 ICG 组。每一病例入选后,按照有专人负责:确定病例的入组,同时通知研究者 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Generate a treatment allocation sequence (ICG group vs. non-ICG group, 1:1 ratio) for 60 cases with unique serial IDs (01–60), ensuring centralized data storage and real-time researcher notification. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
单盲(对受试者隐藏分组),对评估者隐藏分组 |
|
Blinding: |
Single-Blind Design (Blinding of Participants and Assessors) |
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
ResMan,论文发表后一年内, http://www.medresman.org.cn/login.aspx。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
ResMan, within one year of publication, http://www.medresman.org.cn/login.aspx. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
CRF设计特点: 1.ICG特异性字段: 荧光强度分级(标准化评分表)、淋巴结误染率、非荧光组假阴性率计算。 2.盲法病理评估: 病理报告页隐藏荧光分组信息,减少偏倚。 3.纸质CRF应急: 术中实时填写纸质表格(如设备故障时),24小时内转录至EDC。 数据管理流程: 1.采集: 术中数据由手术助手通过EDC平板端实时录入(如荧光显影时间、清扫站数)。 病理数据由研究协调员扫描上传报告,EDC自动解析关键字段(转移淋巴结数)。 2.存储: 数据库加密(AES-256),影像数据脱敏后独立存储(保留原始手术录像≥10年)。 3.质控: 每周生成数据缺失报告(如未填并发症分级),锁定72小时未修正的CRF。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF Design Features: 1.ICG-Specific Fields: Fluorescence intensity grading (standardized scoring scale),Lymph node false staining rate,Calculation of false-negative rate in non-fluorescence group 2.Blinded Pathological Evaluation: Fluorescence grouping information concealed in pathology report pages to reduce bias 3.Paper CRF for Emergencies: Intraoperative real-time paper form completion (e.g., during equipment failure) Transcription to EDC within 24 hours Data Management Process: 1.Collection: Intraoperative data entered in real-time by surgical assistants via EDC tablets (e.g., fluorescence imaging time, number of dissected stations) Pathology data uploaded by study coordinators via scanned reports, with EDC auto-parsing key fields (e.g., number of metastatic lymph nodes) 2.Storage: Encrypted database (AES-256) Anonymized imaging data stored separately (raw surgical videos retained for ≥10 years) 3.Quality Control: Weekly generation of missing data reports (e.g., unfilled complication grades) Locking of CRFs with uncorrected data after 72 hours |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |